Wolverine Trading, LLC Spectrum Pharmaceuticals Inc Transaction History

Wolverine Trading, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.43 - $1.56 $3,621 - $13,136	8,421 Added 59.39%	22,599 $10,000
Q2 2022 Aug 15, 2022	BUY	$0.7 - $1.4 $2,778 - $5,556	3,969 Added 38.88%	14,178 $11,000
Q1 2022 May 16, 2022	SELL	$0.63 - $1.59 $4,401 - $11,107	-6,986 Reduced 40.63%	10,209 $13,000
Q4 2021 Feb 14, 2022	BUY	$1.27 - $2.42 $8,084 - $15,405	6,366 Added 58.79%	17,195 $23,000
Q2 2021 Aug 06, 2021	SELL	$2.89 - $4.45 $39,699 - $61,129	-13,737 Reduced 55.92%	10,829 $42,000
Q3 2020 Nov 13, 2020	BUY	$2.99 - $4.9 $11,804 - $19,345	3,948 Added 19.15%	24,566 $103,000
Q2 2020 Aug 13, 2020	SELL	$2.11 - $3.38 $22,965 - $36,787	-10,884 Reduced 34.55%	20,618 $64,000
Q1 2020 May 11, 2020	SELL	$1.83 - $3.45 $43,109 - $81,271	-23,557 Reduced 42.79%	31,502 $72,000
Q4 2019 Feb 12, 2020	BUY	$3.5 - $10.35 $145,981 - $431,688	41,709 Added 312.43%	55,059 $197,000
Q3 2019 Nov 14, 2019	BUY	$7.03 - $9.7 $93,850 - $129,494	13,350 New	13,350 $118,000
Q4 2017 Feb 14, 2018	SELL	$13.36 - $20.73 $388,802 - $603,284	-29,102 Closed	0 $0
Q3 2017 Nov 15, 2017	BUY	$8.75 - $14.07 $254,642 - $409,465	29,102	29,102 $409,000

115K

Ticker SPPI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,164,000
Description
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor ...

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Trading, LLC with notifications on news.